Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 669 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR 3 Steps to Making the Right Decisions for You During Cancer:... February 8, 2024 Meet the teams tackling 5 challenges in children’s and young people’s... March 18, 2021 Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... July 5, 2023 Treatment for Oropharyngeal Cancer: Investigating Ways to Do Less Harm May 20, 2021 Load more HOT NEWS Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού; Dabrafenib–Trametinib Combination Approved for Melanoma, Anaplastic Thyroid Cancer EMA Recommends Granting a Marketing Authorisation for Zolbetuximab What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling
